Your session is about to expire
← Back to Search
Trametinib + Paclitaxel for Thyroid Cancer
Study Summary
This trial is testing a new combination cancer treatment to see if it is safe and effective against Anaplastic Thyroid Cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with HIV, HBV, or HCV.I do not have any unmanaged ongoing illnesses.I have a condition that affects my ability to absorb pills.Women who can have babies must have a negative pregnancy test within 14 days before joining the study.I have not had chemotherapy or radiotherapy in the last 7 days.I do not have symptoms or untreated issues with brain metastases, leptomeningeal disease, or spinal cord compression.I have a history of heart problems or am at risk for them.I have not had major surgery in the last 3 weeks.I am not using any medications or therapies that are not allowed.My cancer has spread and cannot be surgically removed with the aim of cure.I am 18 years old or older.I can take care of myself but might not be able to do heavy physical work.I can swallow and keep down pills.My organ and bone marrow functions are normal.My diagnosis is anaplastic thyroid cancer.You have a disease that can be measured using specific criteria.I do not have major stomach or intestine problems.You do not have severe neuropathy based on a specific grading system.I have or am at risk for eye conditions like RVO or CSR.I have had interstitial lung disease or pneumonitis.You have had a bad reaction to taxanes, trametinib, or similar drugs, or to the ingredients in the study drug.
- Group 1: Trametinib in Combination With Paclitaxel
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What ailment is Trametinib usually utilized to treat?
"Trametinib is an effective treatment option for neoplasm metastasis, Kaposi sarcoma, and advance directives."
Are there any vacancies left for participants in this experiment?
"This medical research has ceased patient recruitment and was last modified on March 10th 2022. If you're looking for another study, there are 230 trials actively enrolling patients with thyroid cancer while 922 studies related to Trametinib need participants."
Are there various health facilities in the U.S. that are conducting this medical investigation?
"Seven medical centres are currently enrolling patients in this trial. These include the Memorial Sloan Kettering Westchester (Limited Protocol Activities) facility in Harrison and the Memorial Sloan Kettering Cancer Centre in New york, as well as 5 other sites scattered across America."
How many participants is the clinical trial currently allowing to join?
"Recruitment for this trial has since been suspended. It was initially posted on March 15th 2017 and modified lastly on the 10th of March 2022. If you seek out other studies, there are currently 230 active clinical trials enrolling individuals who have thyroid cancer, anaplastic carcinoma, or Trametinib-related malignancies."
Are there any other trials of Trametinib that have been conducted to date?
"Presently, there are 922 active trials for Trametinib and 233 in their final phase. Although many of these experiments are happening in Woolloongabba, Queensland, the exploration of this drug is taking place across 51124 different sites worldwide."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger